COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation

Rosa, David de la; Olveira, Casilda; García‐Clemente, Marta; Girón‐Moreno, Rosa‐María; Nieto-Royo, Rosa; Navarro, Annie; Prados‐Sánchez, Concepción; Sibila, Oriol; Martínez-García, Miguel-Ángel

doi:10.1016/j.chest.2019.08.1916

Cited by 18 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a recent correlation study of quality of life in bronchiectasis reported a correlation between CAT and BHQ scores and showed similar results to the correlation between K-BHQ and K-CAT in this study [ 14 ].…”

Section: Discussionsupporting

confidence: 86%

Validation of the Korean Version of the Bronchiectasis Health Questionnaire

et al. 2020

View full text Add to dashboard Cite

Background: The Bronchiectasis Health Questionnaire (BHQ) is a simple and repeatable, self-reporting health status questionnaire for bronchiectasis. We have translated the original version of the BHQ into Korean using a standardized methodology. The purpose of this study was to assess the validity of the Korean version of the BHQ (K-BHQ) with Korean patients. Methods: Stable state patients with bronchiectasis from two academic hospitals were enrolled in this study. The validity was assessed by investigating the relationship between the K-BHQ scores and the Korean version of the Chronic Obstructive Pulmonary Disease Assessment Test (K-CAT) scores. We also investigated the relationship between the K-BHQ scores and other variables of the modified Medical Research Council' s (mMRC) dyspnea scale, lung function, and exacerbations. Results: A total of 126 patients with bronchiectasis were enrolled. The mean age was 64.3 (standard deviation [SD], 9.7). Women comprised 53.2% of the patients. The mean forced expiratory volume in one second (FEV 1) was 60% of the predicted value (SD, 18.9%); the mean K-CAT score was 17.6 (SD, 9.1). The K-BHQ scores correlated strongly with the K-CAT scores (r=-0.656, p<0.001). There was significant correlation between the K-BHQ scores and the mMRC dyspnea scale (ρ=-0.409, p<0.001), FEV 1 (r=0.406, p<0.001), and number of exacerbations requiring hospitalization (ρ=-0.303, p=0.001). Conclusion: The K-BHQ is valid for assessing the health-related quality of life or health status of Korean bronchiectasis patients.

show abstract

Section: Discussionsupporting

confidence: 86%

Validation of the Korean Version of the Bronchiectasis Health Questionnaire

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In parallel with our study, another validation study of the CAT in bronchiectasis has recently been conducted in Spain. This study by De La Rosa Carrillo 36 found that the CAT had excellent internal consistency and repeatability and correlated well with other questionnaires, including the bronchiectasis health questionnaire and SGRQ and QOL-B. The authors proposed an MCID of 3 points based on two measures of distribution of the change in CAT score around exacerbation.…”

Section: Discussionmentioning

confidence: 97%

“…The two studies used a different design and different methods of analysis and therefore provide complementary information on the utility of the CAT in bronchiectasis. 36 Our study is limited by the questionnaires being administered in English and only with patients in the United Kingdom. Nevertheless, the characteristics of the patients are broadly representative of those in larger bronchiectasis patient populations across Europe.…”

Section: Discussionmentioning

confidence: 99%

Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis

Finch

Laska

Abo-Leyah

et al. 2020

Chest

View full text Add to dashboard Cite

BACKGROUND: Objective assessment of symptoms in bronchiectasis is important for research and in clinical practice. The COPD Assessment Test (CAT) is a short, simple assessment tool widely used in COPD. The items included in the CAT are not specific to COPD and also reflect the dominant symptoms of bronchiectasis. We therefore performed a study to validate the CAT as an outcome measure in bronchiectasis. METHODS: The CAT was administered to two cohorts of bronchiectasis patients along with other quality of life questionnaires. Patients underwent comprehensive clinical assessment. One cohort had repeated questionnaires collected before-and-after treatment of acute exacerbations. We analyzed convergent validity, repeatability, and responsiveness of the score and calculated the minimum clinically important difference (MCID) using a combination of distribution and anchor-based methods. RESULTS: In both cohorts there were positive correlations between the CAT and the St. George's Respiratory Questionnaire (r ¼ 0.90, P < .0001 and r ¼ 0.87, P < .0001). There was an inverse relationship between CAT and Quality of Life-Bronchiectasis Respiratory Symptoms Scale (r ¼ À0.75, P < .0001) and Leicester Cough Questionnaire score (r ¼ À0.77, P < .0001). Patients with more severe disease, based on the bronchiectasis severity index, had significantly higher CAT scores. CAT also correlated with FEV 1 % predicted and 6-min walk distance (6MWD). CAT increased significantly at exacerbation and fell at recovery. The intraclass correlation coefficient for two measurements four-weeks apart while clinically stable was 0.88 (95% CI, 0.73-0.95, P < .0001). An MCID of 4 was most consistent. CONCLUSIONS: CAT is a valid, responsive symptom assessment tool in bronchiectasis. The MCID is estimated as 4 points.

show abstract

“…The following variables were recorded at the first appointment in the pre-pandemic period and the last in the pandemic, for the purposes of comparison: the quantity and type of expectoration, according to Murray’s classification [ 38 ]; the degree of dyspnea on the mMRC (modified Medical Research Council) scale [ 39 ]; lung function studies (FVC and FEV 1 ); changes in usual treatment; analytical data: leukocytes, neutrophils, eosinophils, erythrocyte sedimentation rate (ESR), fibrinogen, albumin, C-reactive protein (CRP); the FACED [ 40 ] and e-FACED [ 23 ] scores; the BSI (Bronchiectasis Severity Index) score [ 41 ]; and the HADS (Hospital Anxiety and Depression Scale) [ 42 ] and CAT (COPD Assessment Test) questionnaires [ 43 ]. Cut-offs of 11 or less points in the HADS-A or HADS-D questionnaires [ 44 ] and more than 10 in the CAT symptoms questionnaire were considered pathological.…”

Section: Methodsmentioning

confidence: 99%

Impact of the SARS-CoV-2 Virus Pandemic on Patients with Bronchiectasis: A Multicenter Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Infection by SARS-CoV-2 has unquestionably had an impact on the health of patients with chronic respiratory airway diseases, such as COPD and asthma, but little information is available about its impact on patients with bronchiectasis. The objective of the present study was to analyze the effect of the SARS-CoV-2 pandemic on the state of health, characteristics, and clinical severity (including the number and severity of exacerbations) of patients with non-cystic fibrosis bronchiectasis. Methods: This study was multicenter, observational, and ambispective (with data collected before and during the SARS-CoV-2 pandemic), and included 150 patients diagnosed with non-cystic fibrosis bronchiectasis. Results: A significant drop was observed in the number and severity of the exacerbations (57% in all exacerbations and 50% in severe exacerbations) in the E-FACED and BSI multidimensional scores, in the pandemic, compared with the pre-pandemic period. There was also a drop in the percentage of sputum samples positive for pathogenic microorganisms in general (from 58% to 44.7%) and, more specifically, Pseudomonas aeruginosa (from 23.3% to 13.3%) and Haemophilus influenzae (from 21.3% to 14%). Conclusions: During the SARS-CoV-2 period, a significant reduction was observed in the exacerbations, severity, and isolations of pathogenic microorganisms in patients with bronchiectasis.

show abstract

COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation

Cited by 18 publications

References 34 publications

Validation of the Korean Version of the Bronchiectasis Health Questionnaire

Validation of the Korean Version of the Bronchiectasis Health Questionnaire

Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis

Impact of the SARS-CoV-2 Virus Pandemic on Patients with Bronchiectasis: A Multicenter Study

Contact Info

Product

Resources

About